Some good pics from the ID week presentation included on the company twitter
https://twitter.com/Synairgenplc/status/1585890916396662786?t=eEKokAwYE6RgfPDn8RZCYg&s=19
My pleasure Joey
For those not bothered to click through, do note the disclaimer at the top of the session
"Abstracts are Embargoed until October 19 at 8 a.m. ET; Late Breaker Abstracts are Embargoed until the date and time of the presentation.*
https://www.eventscribe.net/2022/IDWeek/agenda.asp?startdate=10/21/2022&enddate=10/21/2022&BCFO=M&pfp=BrowseDay&mode=&fa=&fb=&fc=&fd=
Session: COVID-19 Late Breaking Abstracts
LB1533 - Impact of Treatment of Hospitalised COVID-19 Patients With Inhaled Interferon Beta-1a (SNG001) on Long COVID Symptoms: Results From the SPRINTER trial
Friday, October 21, 2022 2:35 PM – 2:45 PM US ET Location: 209 ABC
Live Stream
All relevant financial disclosures have been mitigated.
This is the para referencing SNG001
"Type I IFNs—In order to trigger the innate immune response, recombinant IFN-
Is, such as IFNa and IFNß, have been widely used in the past and studied in cancer
treatment alone or in combination with chemotherapeutics, both in oncology and onco-
hematology [149–154]. Recombinant IFN-Is are also being actively studied as therapeutic
approaches for COVID-19; in particular, a few studies have assessed the effectiveness
of nebulized IFNß-1a in COVID-19 hospitalized patients. These studies highlight that
receiving IFNß-1a is correlated with earlier recovery and lower incidence of adverse events
and has also been associated with clinical improvement in one study [155,156]. Recent
studies and a meta-analysis underline the positive effects of IFNß administration combined
with other antivirals, such as ribavirin in the early days of virus spreading, resulting in
higher survival rates, lower mechanical ventilation rates, enhanced viral clearance and an-
tiviral response [157,158]. Similarly, a multicenter cohort study investigated the correlation
between early administration of IFNa-2b and antivirals (lopinavir/ritonavir) with a lower
mortality rate when compared with antiviral treatment alone; conversely, patients with
late administration of IFN experienced increased mortality and delayed recovery among
survivors [159]."
There is a considerable amount of literature out there re INF vs Cancer. Understand one of the biggest challenges has been the side effects of systemic inf application in large enough quantity to affect tumors. Maybe they could try putting it directly in to the lungs?
Monk et al referenced
Conclusions
In this review, we have highlighted the immunobiological connections shared by
SARS-CoV-2 infection and cancer. In particular, we have underlined the dynamic involve-
ment of different cytokines and immune system pathways at different disease stages in
both conditions, and pinpointed the most relevant therapeutic intersections. These interdis-
ciplinary considerations warrant attention for the development of future research avenues,
which could take into account the clinical challenges stemming from enduring/frustrated
chronic immune responses in COVID-19 and cancer, to develop novel therapeutic strategies
to tackle the chronicization of immune responses in both disease settings.
https://www.google.com/url?sa=t&source=web&rct=j&url=https://www.mdpi.com/2227-9059/10/10/2628/pdf%3Fversion%3D1666173275&ved=2ahUKEwj9mai_w-z6AhUemFYBHURRADM4ChAWegQIBBAB&usg=AOvVaw2dLHpzv8OYIeaykSNbN07B
After the press release stating Ray was onboard w SNG the Fri before sprinter results and that strange interview where he cryptically mentioned sng001 and long Covid - he more or less disappeared until a couple of weeks ago, when this site was launched
https://www.putnaminsights.com/
*The researchers analysed blood from 36 Covid patients admitted to Guy’s and St Thomas’ NHS Foundation Trust in London in the first wave of the pandemic. They found that levels of a protein called IL-6, which immune cells release as a rallying call for other immune cells, were more than 15 times higher than normal in infected individuals.
But an even more dramatic rise in IL-6 was found in Covid patients with delirium – a state of extreme confusion that can leave people not knowing who, or where, they are. In these patients, IL-6 was six times higher than in other Covid patients. Nearly a third of Covid patients admitted to hospital experience delirium, rising to two-thirds in severe cases."
https://www.theguardian.com/world/2022/oct/05/immune-reactions-to-severe-covid-may-trigger-brain-problems-study-finds
Penny for anyone's thoughts on how to target the IL-6 Pathway
Thank you for doing the maths Tommy
Before anyone makes a comment about combining trial data - From today's RNS
[2] Synairgen conducted a trial of SNG001 in high-risk, home-based COVID-19 patients (SG016) in which fewer patients treated with SNG001 were hospitalised (0/56) compared to placebo (2/58). In total across SG016 and ACTIV-2, 1/165 SNG001-treated home-based COVID-19 patients have been hospitalised
In the "about Activ 2" section
Have they buried the lede???
*[2] Synairgen conducted a trial of SNG001 in high-risk, home-based COVID-19 patients (SG016) in which fewer patients treated with SNG001 were hospitalised (0/56) compared to placebo (2/58). In total across SG016 and ACTIV-2, 1/165 SNG001-treated home-based COVID-19 patients have been hospitalised."
1 patient off of 100% RRR
Cheers Wigster, I had seen that 28th was just an evening for informal networking but couldn't find any schedule for today and tomorrow. It appears the company are the only ones presenting any kind of trial data so I guess it makes sense to save it for Friday and make sure punters stick around.
It is a bit of a peculiar one this, seems multiple times smaller than what the company have presented at earlier this year and have lined up for the coming months, but of course the topic is exactly what they do. Who would be attending that they would want to speak with?
I'm also intrigued by the the presentation title, just as it's not one we've seen before, anyone's guess if it includes new data.
Non-Executive Director
Dr Flic Gabbay is an independent non-executive director of Synairgen since September 2022. Flic has extensive experience within the life sciences sector including holding several senior and CEO positions in big pharma, biotech and CROs in both Europe and North America. As Founder and Managing Partner at TranScrip LLP, founded in 2008, she has overseen drug development work with companies at all stages of the drug development cycle, as well as securing private equity investment and the acquisition of Real Regulatory.
Starting her career as a medical doctor, Flic held various medical posts across Europe before moving into the biotechnology sector. She is the current President of the Faculty of Pharmaceutical Medicine for the Royal Colleges of Physicians.
In 2020, Flic was awarded the Fellowship of the Academy of Medical Science and is passionate about bringing pharmaceutical medicine into mainstream medical science and its application to public health.
She completed a BSc in Pharmacology and a Bachelor of Medicine and Surgery degree at the University of Manchester.